Mahtiyan, Elham
MD, Psychiatrist, fellowship in Psychotherapy, Psychiatry and Behavioral Sciences Research Center, Addiction Institute and Department of Psychiatry; Faculty of Medicine Mazandaran University of Medical Sciences, Sari, Iran.
[ 1 ] - Evaluation of the efficacy and safety of pregabalin as an adjuvant to antipsychotics in patients with chronic schizophrenia: a six-week pilot double-blind placebo-controlled trial
Introduction and objectives: Antipsychotics or dopamine receptor antagonists are the major components of treatment but about 10-20% of patients with schizophrenia do not benefit from treatment with antidopaminergic agents, indicating other neuronal systems may be involved in this disorder (2). Dysregulation of both excitatory and inhibitory mechanisms N-Methyl-D-aspartic acid (NMDA) and γ-Amino...
نویسندگان همکار